Cystic fibrosis variants protect against inflammatory bowel disease
Author Information
Author(s): Yu Mingrui, Zhang Qian, Yuan Kai, Sazonovs Aleksejs, Stevens Christine, Fachal Laura, Anderson Carl A., Daly Mark J., Huang Hailiang
Primary Institution: Massachusetts General Hospital
Hypothesis
Variants impairing CFTR function are protective against inflammatory bowel disease (IBD).
Conclusion
The study provides conclusive evidence that cystic fibrosis risk variants confer a protective effect against inflammatory bowel disease.
Supporting Evidence
- CF-risk variants were found to have a significant protective effect against IBD.
- The protective effect of the CFTR deltaF508 variant reached genome-wide significance.
- Meta-analysis confirmed the protective role of CF-risk variants in IBD.
- Variant prioritization methods were assessed to enhance the power of burden tests.
- Clinical annotations from the CFTR2 database were crucial for establishing the protective effect.
Takeaway
Some genetic changes that cause cystic fibrosis might actually help protect people from getting inflammatory bowel disease.
Methodology
The study used exome sequencing data from a large cohort of IBD cases and controls to assess the protective role of CF-risk variants.
Potential Biases
Potential over-representation of CF patients in the Broad study could create a spurious association.
Limitations
The study may be confounded by ascertainment bias in CF patients and the quality of variant annotations.
Participant Demographics
The study primarily involved individuals of European ancestry.
Statistical Information
P-Value
8.96E-11
Confidence Interval
95% CI: 0.73 – 0.85
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website